Which agents are used in second-line therapy for renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

A number of agents are available to be used in second and subsequent lines of therapy, these include anti-angiogenic therapy (if not already used in first-line treatment), nivolumab, cabozantinib, and mTOR inhibitors. Recommendations regarding how to sequence approved agents during subsequent therapy are evolving; more work is needed. Clinical trials are currently exploring future directions, including combinations of approved agents and the optimal sequencing of these agents.

Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these topics.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!